UPDATE January 2019: Documents filed in court show that Monsanto provided Kate Kelland with the documents for her June 2017 story about Aaron Blair and gave her a slide deck of talking points the company wanted covered. For more details, see Carey Gillam’s Roundup Trial Tracker post.
The following analysis was prepared by Carey Gillam and posted June 28, 2017:
A June 14, 2017 Reuters article authored by Kate Kelland, headlined “The WHO’s cancer agency left in the dark over glyphosate evidence,” wrongly accused a cancer scientist of withholding important data in the safety assessment of glyphosate conducted by the International Agency for Research on Cancer (IARC).
Kelland’s story contains factual errors and states conclusions that are contradicted by a full reading of the documents she cited as primary sources. It is notable that Kelland provided no link to the documents she cited, making it impossible for readers to see for themselves how far she veered from accuracy in interpreting them. The primary source document clearly contradicts the premise of Kelland’s story. Additional documents her story referenced, but also did not link to, can be found at the end of this post.
Background: The Reuters story was one in a series of critical pieces the news agency has published about IARC that Kelland wrote after IARC classified glyphosate as a probable human carcinogen in March 2015. Glyphosate is a highly profitable chemical herbicide used as the main ingredient in Monsanto’s Roundup weed killing products, as well as hundreds of other products sold around the world. The IARC classification triggered mass litigation in the United States brought by people alleging their cancers were caused by Roundup, and prompted the European Union and U.S. regulators to deepen their evaluation of the chemical. In response to the IARC classification, and as a means of defending itself against the litigation and shoring up regulatory support, Monsanto has lodged multiple complaints against IARC seeking to undermine IARC’s credibility. The June 14 Kelland story, which quoted a top Monsanto “strategy” executive, furthered those strategic efforts and has been touted by Monsanto and others in the chemical industry as proof that the IARC classification was flawed.
- A deposition of scientist Aaron Blair, a draft abstract and email communication Kelland references in her story as “court documents” were not in fact court documents but were documents created and obtained as part of discovery in the multidistrict litigation brought by the cancer victims who are suing Monsanto. The documents were held in the possession of Monsanto’s legal team as well as plaintiffs’ legal team. See docket U.S. District Court for the Northern District of California, lead case 3:16-md-02741-VC. If Monsanto or a surrogate provided the documents to Kelland, such sourcing should have been cited. Given that the documents were not obtained through the court, as Kelland’s story implies, it seems apparent Monsanto or surrogates planted the storyline and provided Kelland with the documents, or at least selected parts of the documents, along with its assessment of them.
- Kelland’s article provides commentary and an interpretation of the deposition from Bob Tarone, whom Kelland describes as “independent of Monsanto.” Yet information provided by IARC establishes that Tarone has acted as a paid consultant to Monsanto on its efforts to discredit IARC.
- Reuters teased the story with this statement: “The scientist leading that review knew of fresh data showing no cancer link – but he never mentioned it and the agency did not take it into account.” Kelland implied that Dr. Blair was intentionally hiding critical information. Yet the deposition shows that Blair testified that the data in question was “not ready” to submit to a journal for publication and would not be allowed for consideration by IARC because it had not been finished and published. Much of the data was gathered as part of a broad U.S. Agricultural Health Study and would have been added onto several years of previously published information from the AHS that showed no association between glyphosate and non-Hodgkin lymphoma. A Monsanto lawyer questioned Blair about why the data wasn’t published in time to be considered by IARC, saying: “You decided, for whatever reason, that that data was not going to be published at that time, and therefore was not considered by IARC, correct?” Blair replied: “No. Again you foul up the process.” “What we decided was the work that we were doing on these different studies were not yet — were not yet ready to submit to journals. Even after you decide to submit them to journals for review, you don’t decide when it gets published.” (Blair deposition transcript page 259) Blair also said to the Monsanto attorney: “What is irresponsible is to rush something out that’s not fully analyzed or thought out” (page 204).
- Blair also testified that some data from the unfinished, unpublished AHS was “not statistically significant” (page 173 of deposition). Blair also testified in that deposition about data showing strong connections between glyphosate and NHL that also was not disclosed to IARC because it was not published.
- Blair testified that some data from a North American Pooled Project study showed a very strong association with NHL and glyphosate, with a doubling and tripling of risk associated with the pesticide seen in people who used glyphosate more than twice a year. Just as the AHS data, this data was also not published or given to IARC (pages 274-283 of Blair deposition).
- Kelland’s article also states: “Blair also said the data would have altered IARC’s analysis. He said it would have made it less likely that glyphosate would meet the agency’s criteria for being classed as ‘probably carcinogenic.’” That testimony (on pages 177-189 of deposition) does not support those statements at all. Blair ultimately says “probably” to questioning from Monsanto’s attorney asking if the 2013 AHS data had been included in a meta-analysis of epidemiology data considered by IARC, if that “would have lowered the meta-relative risk for glyphosate and non-Hodgkin lymphoma even further…” Kelland’s story also leaves the impression that this unpublished epidemiology data from an unfinished study would have been a game-changer for IARC. In fact, reading the deposition in full, and comparing it to IARC’s report on glyphosate, underscores how false and misleading that notion is. Blair testified only to epidemiology data and IARC had already deemed the epidemiology evidence that it did see as “limited.” Its classification of glyphosate saw significance in the animal (toxicology) data it reviewed, deeming it “sufficient.”
- Kelland ignores important portions of the Blair deposition specific to a published 2003 study that found “there was over a doubling of the risk of non-Hodgkin’s lymphoma for people who had been exposed to glyphosate” (pages 54-55 of the deposition).
- Kelland ignores testimony in the Blair deposition regarding a “300 percent increased risk” for cancer in Swedish research (page 60 of deposition).
- Reading through the entire deposition shows that Blair testified as to many examples of studies showing a positive association between glyphosate and cancer, all of which Kelland ignored.
- Kelland writes that in his legal testimony, Blair also described the AHS as “powerful” and agreed the data showed no link to cancer. She implied he was speaking of the specific unpublished 2013 data on NHL and glyphosate that is a tiny subset of information obtained from the AHS, when in fact the testimony shows he was speaking of the larger AHS umbrella of work, which has been tracking farm families and collecting data on dozens of pesticides for several years. What Blair actually said of the broad AHS was this: “ “It’s — it’s a powerful study. And it has advantages. I’m not sure I would say it is the most powerful, but it is a powerful study.” (page 286 of deposition)
- Furthermore, when speaking directly of the 2013 AHS data on glyphosate and NHL, Blair confirmed that the unpublished data needed “cautious interpretation” given the number of exposed cases in subgroups was “relatively small” (page 289).
- Kelland states “IARC told Reuters that, despite the existence of fresh data about glyphosate, it was sticking with its findings,” suggesting a cavalier attitude. Such a statement is entirely misleading. What IARC in fact said was its practice is not to consider unpublished findings and that it can re-evaluate substances when a significant body of new data is published in literature.
- Monsanto Spin Doctors Target Cancer Scientist in Flawed Reuters Story, by Carey Gillam (June 2017)
- Reuters Vs. UN Cancer Agency: Are Corporate Ties Influencing Science Coverage? by Stacy Malkan (July 2017)
- More misleading claims about IARC reported in Reuters by Kate Kelland, USRTK (October 2017)